Maybe BB can start by going here. Archived Conten
Post# of 9122
(Total Views: 474)
Posted On: 02/06/2018 12:27:03 PM
Maybe BB can start by going here.
Archived Content
Emerging Diagnostic Partnering and Investment Forum
Partnering Forum - Home | View Agenda | Download Partnering Forum Brochure
Aviana Molecular Technologies
Aviana Aviana Molecular Technologies (Aviana) is a development stage diagnostic company developing a unique approach to point of care diagnosis. Aviana' product has are no moving parts and importantly, sample processing is very simple. Aviana's reader will be a small, hand held device which can be used in any health care setting. Aviana's biosensor is based on a proprietary creative and innovative adaptation of chips made for cellular communication. Furthermore, the established electronics industry provides a basis for mass manufacture which is augmented by Aviana's proprietary, scalable biofilm coating processes. Given the simplicity of use and potentially high sensitivity, Aviana believes that its technology can detect specific infections within 20 minutes or less. Our goal is to provide results comparable to a lab based test. Aviana's biosensor is simple, cost-effective and holds great promise for development as POC diagnostic tool for use in both the developed world and resource limited settings. Our goal is to Test Anywhere, Everywhere. We leverage the convergence of wireless communications and miniature computing in developing our technology. We believe that the impending changes in health care can benefit from a POC tool like Aviana's. In particular, the development and implementation of POC testing for infectious diseases would have a huge impact not only on public health concerns but also for "routine" clinical situations and help control health care costs.
Novel technology and/or applications: Aviana is developing a unique biosensor which is both proprietary and simple to use. Critically, Aviana's biosensor, unlike many other POC systems in development, is entirely electronic, translating a specific biological action directly into an electronic signal without the need for any other intervening technologies like optical or magnetic systems, which, in most systems, are needed to amplify and create bulky and complex systems.
Type of partnerships sought: Strategic Alliances for development of point of care companion diagnostics in infectious diseases or point of care diagnostics for non-infectious diagnostics
InstantLabs
Instant Labs InstantLabs is a molecular diagnostic device company and the developer of next-generation portable Real-Time PCR (RT-PCR) systems. The company is initially focused on food safety and medical diagnostic applications for its technologies. InstantLabs currently markets its Hunter Accelerated-PCR® platform with disposable Multiple Assay Cartridges (MACs), bringing simplicity and power to complex diagnostic testing without dependency on central laboratories or acute care facilities. The compact, affordable and fully integrated Hunter system is especially suited for use at points-of-care and points-of-need, to detect and analyze a wide variety of common and problematic pathogens. InstantLabs is positioned to broaden the addressable market for RT-PCR in areas where gold-standard accuracy combined with ease-of-use and rapid time to results can make a consequential improvement in health outcomes as well as operational efficiency.
Novel technology and/or applications: InstantLabs is focused on making PCR available at the point-of-need and point-of-care. We have available for sale food safety test kits approved by the AOAC. We are now looking to bring the same key benefit, quicker time to results with an easy to use and affordable device into human diagnostics. Our first test will be for the detection of MRSA, allowing hospitals to quickly identify patients that are infected before they enter the facility.
Type of partnerships sought: InstantLabs seeks partners that can provide capital to fund operations and the the cost of the 510-k FDA approval. We also seek partners that can help with distribution once the assay is fully developed.
MZ Diagnostics
MZ Diagnostics MZ Diagnostics was formed in early 2011 to develop and commercialized FDA approved applications for use on Mass Spectrometry systems in hospital and clinical labs. Our approach uses mass spectrometry to detect specific and highly conserved physical changes in carbapenem class of antibiotics associated with enzymatic inactivation. By detecting loss of antibiotic function, and avoiding PCR, gene sequencing or protein analysis, we can eliminate the major short comings of currently available methods and deliver results in a significantly shorter time frame than is currently possible across a variety of enzyme families. This technology was discovered at Yale University and licensed exclusively to MZ Diagnostics.
Novel technology and/or applications: MZ Diagnostics' first product addresses the lack of a reliable rapid test to identify antimicrobial resistance among disease causing bacteria. We have developed a novel rapid phenotypic assay using mass spectrometry (MS) to detect the production of bacterial enzymes that inactivate carbapenems conferring antimicrobial resistance.
Type of partnership sought: Investment capital
Xagenic
Xagenic Xagenic is a venture-backed startup company founded in 2010 to commercialize a chip-based platform for molecular analysis with unprecedented sensitivity, speed and simplicity.
Novel technology concepts and/or applications: The Xagenic technology is highly versatile and has been validated against a variety of cell and sample types.
Type of partnerships sought: Marker and content partners.
IVDiagnostics
IV Diagnostics IVDiagnostics is focused on molecular diagnostics for blood borne diseases. Our initial field of interest is metastatic cancer, but our platform is extensible to infectious and inflammatory diseases.
Novel technology concepts and/or applications: The IVDx system utilizes in vivo technology. We can scan one liter of a patient's blood without taking blood. Our molecular diagnostic platform uses aptamers applied to captured CTCs.
Type of partnerships sought: We are interested in working with pharmaceutical and diagnostics companies looking to create and market highly sensitive diagnostics that assist physicians with personalized treatment.
Epic Sciences
Epic Circulating tumor cells ("CTCs"
are of great interest because they hold the promise to radically improve the treatment of cancer and accelerate the development of personalized medicines. Specifically, CTCs provide a real-time tumor biopsy that is both easily accessible and something that can be monitored routinely throughout the course of the disease. CTC counts have been validated as a prognostic tool in breast and prostate cancer. New technologies, including the Epic technology, are seeking to go beyond enumeration to molecularly characterize the CTCs.
CTC characterization is receiving significant attention because it may provide a real-time assessment of each individual patient's tumor. That information could be used both to guide treatment decisions for individual patients and to guide inclusion/exclusion decisions for clinical trials. The key is will be the availability of a CTC technology that finds enough CTCs in enough patients and in a format that will facilitate downstream CTC characterization. The Epic CTC platform has been designed for that purpose.
AnalizaDx
AnalizaDx AnalizaDx is developing a series of effective cancer diagnostics products focusing on structural changes to protein biomarkers using simple, cost effective, proprietary technology called Solvent Interaction Analysis.
Novel technology concepts and/or applications: Solvent Interaction Analysis is a novel technology for rapidly and effectively discover and utilize changes to protein structure of clinical relevance to cancer diagnostics in complex heterogeneous matrices and biofluids
Type of partnerships sought: We seek strategic partnerships and R&D relationships for developing and commercializing clinically validated biomarkers in cancer, including prostate (complete), breast (late stage development), ovarian, colon, and pancreatic cancers (discovery). We also seek strategic and institutional investments.
GeneCentric Diagnostics
GeneCentricThe mission of GeneCentric Diagnostics is to develop and commercialize novel molecular diagnostic assays that enable oncologists and their patients make more informed, individualized treatment decisions.
Novel technology concepts and/or applications: New targeted therapies have changed the need for classifying lung cancer, primarily for distinguishing the two main categories of non small cell lung cancer (NSCLC), adenocarcinoma from squamous cell carcinoma. GeneCentric has developed a molecular subtype assay that can be performed on routinely available formalin-fixed paraffin-embedded (FFPE) tissues and subdivides lung cancers into clinically relevant categories.
Type of partnerships sought: GeneCentric has already executed its first sublicense, and is looking for additional partnerships to expand its technology base and commercialization strategies.
Genomic Expression
Genomic Expression Genomic Expression is developing inexpensive hypothesis free biomarker discovery tools that make research more effective and predict patient response to particular drugs based on detection of single stranded tags.
Novel technology and/or applications: Genomic Expression's hypothesis-free biomarker-discovery platform is addressing the sample prep and data analysis bottlenecks in current sequencing platforms. Focusing on whole transcriptome analysis Genomic Expression is using intelligent target-filtering technology integrated with sequencing short reads on a small chip. Since all possible sequences are decoded, no assumptions need to be made about which ones will be informative – i.e., biomarker discovery can proceed in a hypothesis-free fashion – and even samples of unknown sequence (e.g., from microbiome samples) can be analyzed.
Type of partnerships sought: Genomic Expression is interested in partnering with pharma as well as diagnostic companies. For pharma, we can deliver a superior and more rational biomarker-discovery process that de-risks the compound in clinic while delivering the same platform all the way to the doctor's office. For diagnostic companies we can provide access to technology platform and superior biobank infrastructure, which includes access to 15 million samples associated with electronic medical records that were established a decade ago – the other side of the data equation. Genomic Expression is also interested in partnering with synergistic technologies in particular in sample prep as well as platforms for manufacturing.
SpeeDx
SpeeDx SpeeDx develops gene detection technology for faster, simpler, and cheaper diagnosis of disease to positively impact humanity world -wide
Novel technology and/or applications: Our key technologies including MNAzymes, DNAzymes and EzyAmp provide the basis for a suite of highly specific and cost-effective methods for analysis of biological materials.
Type of partnerships sought: MNAzymes are available for license from SpeeDx for use in products for human IVD. The company aims to develop assays and platforms and as such we are seeking partners with rights to specific targets and/or devices for detection in a point of care or field setting.
AquaBioChip
AquaBioChip AquaBioChip (DBA SimpleDxWorld) is an MSU spinoff engaged in commercializing Gene-Z and other technologies emanating from the research lab of Dr. Hashsham, a professor at Michigan State University.
Novel technology and/or applications: The technology integrates genomic information, isothermal amplification, simple optics for real time monitoring, microfluidics, and consumer electronics in a simplified package that works for many applications (genetic diagnostics related to clinical, food, water, and plant pathogens) under field conditions.
Type of partnerships sought: Partnerships sought at this stage are related to investment, manufacturing, and sales/distribution.
Adarza
Adarza Adarza has developed a proprietary technology and product platform for biological detection that enables higher levels of differentiating analytical and workflow performance at an industry leading per analyte low cost. Adarza's novel Arrayed Imaging ReflectometryTM technology enables product benefits that will drive adoption through multiple product formats in diverse end-user environments in both rapidly emerging and existing market segments in Life Science Research, Clinical Research (RUO) and In Vitro Diagnostics.
Novel technology and/or applications: Adarza's game changing technology and product platform promises levels of multiplex performance that cannot be achieved by the leading gold standard technologies and instruments commercially available. Arrayed Imaging ReflectometryTM offers a unique combination of sensitivity and highly multiplex detection on inexpensive microarray substrates. Performance benefits also include short assay times, rapid assay development, and simplified user workflow.
Type of partnerships sought: Adarza is seeking partnerships with leading global IVD companies that would include joint development agreements, sublicensing, and/or investment.
Biocartis
BioCartis Biocartis, a biotech company founded in 2007, is engaged in the development of novel diagnostics technology platforms for low to highly multiplexed detection of molecular-based biomarkers. The Company is focused on the delivery of versatile and compact molecular diagnostic platforms that will make the testing of molecular diagnostics (MDx) easier to perform in a wider range of healthcare settings.
Novel technology and/or applications: Biocartis has two main diagnostic platforms currently in late-stage development:
The Apollo instrument is designed to be a fully automated molecular diagnostics platform that takes as input a wide variety of patient samples, performs lysis of (pathogenic) cells to liberate RNA/DNA, performs nucleic acid purification and specific amplifications, detects amplified RNA/DNA and outputs a fast and accurate diagnosis without any human intervention. Additionally, all required reagents for performing an assay are self contained in a single-use and disposable cartridge. This precludes the need for a specialized lab environment, reagent storage and expert personnel for the operation of a diagnostic assay.
The DMAT multiplex Detection Platform is being designed to support a broad range of biological assays, and is suitable for nucleic acid tests as well as for immunoassays.
Our Multiplex Detection Platform integrates proprietary technologies in the field of semiconductor and microfluidics technologies. The core of the technology consists of digitally encoded silicon microparticles, coated with specific capture molecules. One of the key features of our Multiplex Detection Platform is the ability to simultaneously detect and quantify a large number of biomarkers from the same sample.
Type of partnerships sought: We are interested in collaborating with Pharma for the development of companion Dx tests on our platforms that would complement novel compounds in development.
iCubate, Inc.
iCubate iCubate Inc is a private company located in Huntsville, AL and is focused on developing and commercializing molecular differential diagnostic products that are based on multiplex PCR and a fully automated system.
Novel technology and/or applications: We have developed a patented multiplex PCR method, the arm-PCR (amplicon rescued multiplex PCR), a fully integrated system that perform DNA/RNA extraction, amplification and detection, multiplexed, automated, and in a closed cassette. We integrated arm-PCR and PPI (polymerase preference index) algorithm into a software, the iC-Architect, and made it available free to developers. Once assays developed been validated, we help to distribute them online at iC-Store. Once sold, the developer get 70%.
Type of partnerships sought: We are looking for assay developers, commercializing partners and investors.
MBio Diagnostics
mBio Diagnostics MBio Diagnostics is developing a platform for comprehensive diagnosis at the point of care by integrating panels of measurements in an easy-to-use system, for decentralized testing, from health clinics to the home. Initial products are infectious disease panels with attractive global markets.
Novel technology and/or applications: An elegantly simple biosensor enables highly sensitive multiplex rapid testing, with low cost to manufacture.
Type of partnerships sought: We seek content and marketing partners.
Daktari Diagnostics, Inc.
Daktari Daktari Diagnostics, Inc. is a Boston-based company developing andcommercializing diagnostic tests to address the unmet need in near-patient diagnosticsfor global health conditions, including HIV, hepatitis, tuberculosis, and maternal health. The Company's core innovations in microfluidics and electrochemical sensing enable low-cost, handheld systems for measuring complex analytes directly from whole blood.
Novel technology and/or applications: Daktari has developed novel microfluidic control systems that enable separation of target analytes, like cells, bacteria, and viruses, without sample preparation. Users introduce a drop of blood into Daktari cards, and the handheld instrument completes the assay. In addition, a novel electrochemical sensing method greatly simplifies target detection, eliminating the need for optics or optical reagents. As a result, cell and pathogen detection can be made simple, in a device usable by anyone, anywhere.
Type of partnerships sought: The Company is interested in joint development opportunities for cell- or pathogen-based assays on the Daktari platform. Investors are also welcome to discuss investment opportunities at Daktari.
Surnetics
Surnetics Surnetics is a start-up technology company focused on coating technology for improved fluid delivery, transfer, and analysis in microfluidic and other microscale and nanoscale devices, particularly for in-vitro diagnostics (IVD) in the point-of-care market.
Novel technology and/or applications: We have issued patents and pending patent applications for gradient coating technology which allows for passive flow and analysis of liquids, reducing the required needs and costs of pumps, controllers, and other hardware while improving product consistency and predictability. Surnetics has also developed large-scale methods for creating these precision coatings on materials.
Type of partnerships sought: Surnetics's goal is to partner with development partners to develop application-specific solutions for fluid transport in devices and commercialize them into production at high volume. We are interested in most forms of funding including equity investments from development partners and/or outside investors as well as IP licensing agreements.
EyeNetra
EyeNetra.com Based in Cambridge, MA, EyeNetra is transforming the eye care industry by providing on-demand access to eye care from anywhere at any time, benefiting hundreds of millions around the globe.
Novel technology and/or applications: The first diagnostic is called NETRA-G, an award winning technology based on research at MIT Media Lab that quickly measures for nearsightedness, farsightedness and astigmatism on a mobile phone -- ie measurements for eyeglasses. Through Test2Connect, EyeNetra's cloud-based platform for eye care, and EyeNetra's suite of mobile eye diagnostics, patients can connect to care providers and vendors (eg eyeglass stores, hospitals, doctors, pharmaceuticals, and more) with actionable measurements at or close to home.
Type of partnerships sought: We are looking for venture capital and angel investment as well as partners for distribution, manufacture and clinical evaluations in the US and abroad.
Archived Content
Emerging Diagnostic Partnering and Investment Forum
Partnering Forum - Home | View Agenda | Download Partnering Forum Brochure
Aviana Molecular Technologies
Aviana Aviana Molecular Technologies (Aviana) is a development stage diagnostic company developing a unique approach to point of care diagnosis. Aviana' product has are no moving parts and importantly, sample processing is very simple. Aviana's reader will be a small, hand held device which can be used in any health care setting. Aviana's biosensor is based on a proprietary creative and innovative adaptation of chips made for cellular communication. Furthermore, the established electronics industry provides a basis for mass manufacture which is augmented by Aviana's proprietary, scalable biofilm coating processes. Given the simplicity of use and potentially high sensitivity, Aviana believes that its technology can detect specific infections within 20 minutes or less. Our goal is to provide results comparable to a lab based test. Aviana's biosensor is simple, cost-effective and holds great promise for development as POC diagnostic tool for use in both the developed world and resource limited settings. Our goal is to Test Anywhere, Everywhere. We leverage the convergence of wireless communications and miniature computing in developing our technology. We believe that the impending changes in health care can benefit from a POC tool like Aviana's. In particular, the development and implementation of POC testing for infectious diseases would have a huge impact not only on public health concerns but also for "routine" clinical situations and help control health care costs.
Novel technology and/or applications: Aviana is developing a unique biosensor which is both proprietary and simple to use. Critically, Aviana's biosensor, unlike many other POC systems in development, is entirely electronic, translating a specific biological action directly into an electronic signal without the need for any other intervening technologies like optical or magnetic systems, which, in most systems, are needed to amplify and create bulky and complex systems.
Type of partnerships sought: Strategic Alliances for development of point of care companion diagnostics in infectious diseases or point of care diagnostics for non-infectious diagnostics
InstantLabs
Instant Labs InstantLabs is a molecular diagnostic device company and the developer of next-generation portable Real-Time PCR (RT-PCR) systems. The company is initially focused on food safety and medical diagnostic applications for its technologies. InstantLabs currently markets its Hunter Accelerated-PCR® platform with disposable Multiple Assay Cartridges (MACs), bringing simplicity and power to complex diagnostic testing without dependency on central laboratories or acute care facilities. The compact, affordable and fully integrated Hunter system is especially suited for use at points-of-care and points-of-need, to detect and analyze a wide variety of common and problematic pathogens. InstantLabs is positioned to broaden the addressable market for RT-PCR in areas where gold-standard accuracy combined with ease-of-use and rapid time to results can make a consequential improvement in health outcomes as well as operational efficiency.
Novel technology and/or applications: InstantLabs is focused on making PCR available at the point-of-need and point-of-care. We have available for sale food safety test kits approved by the AOAC. We are now looking to bring the same key benefit, quicker time to results with an easy to use and affordable device into human diagnostics. Our first test will be for the detection of MRSA, allowing hospitals to quickly identify patients that are infected before they enter the facility.
Type of partnerships sought: InstantLabs seeks partners that can provide capital to fund operations and the the cost of the 510-k FDA approval. We also seek partners that can help with distribution once the assay is fully developed.
MZ Diagnostics
MZ Diagnostics MZ Diagnostics was formed in early 2011 to develop and commercialized FDA approved applications for use on Mass Spectrometry systems in hospital and clinical labs. Our approach uses mass spectrometry to detect specific and highly conserved physical changes in carbapenem class of antibiotics associated with enzymatic inactivation. By detecting loss of antibiotic function, and avoiding PCR, gene sequencing or protein analysis, we can eliminate the major short comings of currently available methods and deliver results in a significantly shorter time frame than is currently possible across a variety of enzyme families. This technology was discovered at Yale University and licensed exclusively to MZ Diagnostics.
Novel technology and/or applications: MZ Diagnostics' first product addresses the lack of a reliable rapid test to identify antimicrobial resistance among disease causing bacteria. We have developed a novel rapid phenotypic assay using mass spectrometry (MS) to detect the production of bacterial enzymes that inactivate carbapenems conferring antimicrobial resistance.
Type of partnership sought: Investment capital
Xagenic
Xagenic Xagenic is a venture-backed startup company founded in 2010 to commercialize a chip-based platform for molecular analysis with unprecedented sensitivity, speed and simplicity.
Novel technology concepts and/or applications: The Xagenic technology is highly versatile and has been validated against a variety of cell and sample types.
Type of partnerships sought: Marker and content partners.
IVDiagnostics
IV Diagnostics IVDiagnostics is focused on molecular diagnostics for blood borne diseases. Our initial field of interest is metastatic cancer, but our platform is extensible to infectious and inflammatory diseases.
Novel technology concepts and/or applications: The IVDx system utilizes in vivo technology. We can scan one liter of a patient's blood without taking blood. Our molecular diagnostic platform uses aptamers applied to captured CTCs.
Type of partnerships sought: We are interested in working with pharmaceutical and diagnostics companies looking to create and market highly sensitive diagnostics that assist physicians with personalized treatment.
Epic Sciences
Epic Circulating tumor cells ("CTCs"
are of great interest because they hold the promise to radically improve the treatment of cancer and accelerate the development of personalized medicines. Specifically, CTCs provide a real-time tumor biopsy that is both easily accessible and something that can be monitored routinely throughout the course of the disease. CTC counts have been validated as a prognostic tool in breast and prostate cancer. New technologies, including the Epic technology, are seeking to go beyond enumeration to molecularly characterize the CTCs. CTC characterization is receiving significant attention because it may provide a real-time assessment of each individual patient's tumor. That information could be used both to guide treatment decisions for individual patients and to guide inclusion/exclusion decisions for clinical trials. The key is will be the availability of a CTC technology that finds enough CTCs in enough patients and in a format that will facilitate downstream CTC characterization. The Epic CTC platform has been designed for that purpose.
AnalizaDx
AnalizaDx AnalizaDx is developing a series of effective cancer diagnostics products focusing on structural changes to protein biomarkers using simple, cost effective, proprietary technology called Solvent Interaction Analysis.
Novel technology concepts and/or applications: Solvent Interaction Analysis is a novel technology for rapidly and effectively discover and utilize changes to protein structure of clinical relevance to cancer diagnostics in complex heterogeneous matrices and biofluids
Type of partnerships sought: We seek strategic partnerships and R&D relationships for developing and commercializing clinically validated biomarkers in cancer, including prostate (complete), breast (late stage development), ovarian, colon, and pancreatic cancers (discovery). We also seek strategic and institutional investments.
GeneCentric Diagnostics
GeneCentricThe mission of GeneCentric Diagnostics is to develop and commercialize novel molecular diagnostic assays that enable oncologists and their patients make more informed, individualized treatment decisions.
Novel technology concepts and/or applications: New targeted therapies have changed the need for classifying lung cancer, primarily for distinguishing the two main categories of non small cell lung cancer (NSCLC), adenocarcinoma from squamous cell carcinoma. GeneCentric has developed a molecular subtype assay that can be performed on routinely available formalin-fixed paraffin-embedded (FFPE) tissues and subdivides lung cancers into clinically relevant categories.
Type of partnerships sought: GeneCentric has already executed its first sublicense, and is looking for additional partnerships to expand its technology base and commercialization strategies.
Genomic Expression
Genomic Expression Genomic Expression is developing inexpensive hypothesis free biomarker discovery tools that make research more effective and predict patient response to particular drugs based on detection of single stranded tags.
Novel technology and/or applications: Genomic Expression's hypothesis-free biomarker-discovery platform is addressing the sample prep and data analysis bottlenecks in current sequencing platforms. Focusing on whole transcriptome analysis Genomic Expression is using intelligent target-filtering technology integrated with sequencing short reads on a small chip. Since all possible sequences are decoded, no assumptions need to be made about which ones will be informative – i.e., biomarker discovery can proceed in a hypothesis-free fashion – and even samples of unknown sequence (e.g., from microbiome samples) can be analyzed.
Type of partnerships sought: Genomic Expression is interested in partnering with pharma as well as diagnostic companies. For pharma, we can deliver a superior and more rational biomarker-discovery process that de-risks the compound in clinic while delivering the same platform all the way to the doctor's office. For diagnostic companies we can provide access to technology platform and superior biobank infrastructure, which includes access to 15 million samples associated with electronic medical records that were established a decade ago – the other side of the data equation. Genomic Expression is also interested in partnering with synergistic technologies in particular in sample prep as well as platforms for manufacturing.
SpeeDx
SpeeDx SpeeDx develops gene detection technology for faster, simpler, and cheaper diagnosis of disease to positively impact humanity world -wide
Novel technology and/or applications: Our key technologies including MNAzymes, DNAzymes and EzyAmp provide the basis for a suite of highly specific and cost-effective methods for analysis of biological materials.
Type of partnerships sought: MNAzymes are available for license from SpeeDx for use in products for human IVD. The company aims to develop assays and platforms and as such we are seeking partners with rights to specific targets and/or devices for detection in a point of care or field setting.
AquaBioChip
AquaBioChip AquaBioChip (DBA SimpleDxWorld) is an MSU spinoff engaged in commercializing Gene-Z and other technologies emanating from the research lab of Dr. Hashsham, a professor at Michigan State University.
Novel technology and/or applications: The technology integrates genomic information, isothermal amplification, simple optics for real time monitoring, microfluidics, and consumer electronics in a simplified package that works for many applications (genetic diagnostics related to clinical, food, water, and plant pathogens) under field conditions.
Type of partnerships sought: Partnerships sought at this stage are related to investment, manufacturing, and sales/distribution.
Adarza
Adarza Adarza has developed a proprietary technology and product platform for biological detection that enables higher levels of differentiating analytical and workflow performance at an industry leading per analyte low cost. Adarza's novel Arrayed Imaging ReflectometryTM technology enables product benefits that will drive adoption through multiple product formats in diverse end-user environments in both rapidly emerging and existing market segments in Life Science Research, Clinical Research (RUO) and In Vitro Diagnostics.
Novel technology and/or applications: Adarza's game changing technology and product platform promises levels of multiplex performance that cannot be achieved by the leading gold standard technologies and instruments commercially available. Arrayed Imaging ReflectometryTM offers a unique combination of sensitivity and highly multiplex detection on inexpensive microarray substrates. Performance benefits also include short assay times, rapid assay development, and simplified user workflow.
Type of partnerships sought: Adarza is seeking partnerships with leading global IVD companies that would include joint development agreements, sublicensing, and/or investment.
Biocartis
BioCartis Biocartis, a biotech company founded in 2007, is engaged in the development of novel diagnostics technology platforms for low to highly multiplexed detection of molecular-based biomarkers. The Company is focused on the delivery of versatile and compact molecular diagnostic platforms that will make the testing of molecular diagnostics (MDx) easier to perform in a wider range of healthcare settings.
Novel technology and/or applications: Biocartis has two main diagnostic platforms currently in late-stage development:
The Apollo instrument is designed to be a fully automated molecular diagnostics platform that takes as input a wide variety of patient samples, performs lysis of (pathogenic) cells to liberate RNA/DNA, performs nucleic acid purification and specific amplifications, detects amplified RNA/DNA and outputs a fast and accurate diagnosis without any human intervention. Additionally, all required reagents for performing an assay are self contained in a single-use and disposable cartridge. This precludes the need for a specialized lab environment, reagent storage and expert personnel for the operation of a diagnostic assay.
The DMAT multiplex Detection Platform is being designed to support a broad range of biological assays, and is suitable for nucleic acid tests as well as for immunoassays.
Our Multiplex Detection Platform integrates proprietary technologies in the field of semiconductor and microfluidics technologies. The core of the technology consists of digitally encoded silicon microparticles, coated with specific capture molecules. One of the key features of our Multiplex Detection Platform is the ability to simultaneously detect and quantify a large number of biomarkers from the same sample.
Type of partnerships sought: We are interested in collaborating with Pharma for the development of companion Dx tests on our platforms that would complement novel compounds in development.
iCubate, Inc.
iCubate iCubate Inc is a private company located in Huntsville, AL and is focused on developing and commercializing molecular differential diagnostic products that are based on multiplex PCR and a fully automated system.
Novel technology and/or applications: We have developed a patented multiplex PCR method, the arm-PCR (amplicon rescued multiplex PCR), a fully integrated system that perform DNA/RNA extraction, amplification and detection, multiplexed, automated, and in a closed cassette. We integrated arm-PCR and PPI (polymerase preference index) algorithm into a software, the iC-Architect, and made it available free to developers. Once assays developed been validated, we help to distribute them online at iC-Store. Once sold, the developer get 70%.
Type of partnerships sought: We are looking for assay developers, commercializing partners and investors.
MBio Diagnostics
mBio Diagnostics MBio Diagnostics is developing a platform for comprehensive diagnosis at the point of care by integrating panels of measurements in an easy-to-use system, for decentralized testing, from health clinics to the home. Initial products are infectious disease panels with attractive global markets.
Novel technology and/or applications: An elegantly simple biosensor enables highly sensitive multiplex rapid testing, with low cost to manufacture.
Type of partnerships sought: We seek content and marketing partners.
Daktari Diagnostics, Inc.
Daktari Daktari Diagnostics, Inc. is a Boston-based company developing andcommercializing diagnostic tests to address the unmet need in near-patient diagnosticsfor global health conditions, including HIV, hepatitis, tuberculosis, and maternal health. The Company's core innovations in microfluidics and electrochemical sensing enable low-cost, handheld systems for measuring complex analytes directly from whole blood.
Novel technology and/or applications: Daktari has developed novel microfluidic control systems that enable separation of target analytes, like cells, bacteria, and viruses, without sample preparation. Users introduce a drop of blood into Daktari cards, and the handheld instrument completes the assay. In addition, a novel electrochemical sensing method greatly simplifies target detection, eliminating the need for optics or optical reagents. As a result, cell and pathogen detection can be made simple, in a device usable by anyone, anywhere.
Type of partnerships sought: The Company is interested in joint development opportunities for cell- or pathogen-based assays on the Daktari platform. Investors are also welcome to discuss investment opportunities at Daktari.
Surnetics
Surnetics Surnetics is a start-up technology company focused on coating technology for improved fluid delivery, transfer, and analysis in microfluidic and other microscale and nanoscale devices, particularly for in-vitro diagnostics (IVD) in the point-of-care market.
Novel technology and/or applications: We have issued patents and pending patent applications for gradient coating technology which allows for passive flow and analysis of liquids, reducing the required needs and costs of pumps, controllers, and other hardware while improving product consistency and predictability. Surnetics has also developed large-scale methods for creating these precision coatings on materials.
Type of partnerships sought: Surnetics's goal is to partner with development partners to develop application-specific solutions for fluid transport in devices and commercialize them into production at high volume. We are interested in most forms of funding including equity investments from development partners and/or outside investors as well as IP licensing agreements.
EyeNetra
EyeNetra.com Based in Cambridge, MA, EyeNetra is transforming the eye care industry by providing on-demand access to eye care from anywhere at any time, benefiting hundreds of millions around the globe.
Novel technology and/or applications: The first diagnostic is called NETRA-G, an award winning technology based on research at MIT Media Lab that quickly measures for nearsightedness, farsightedness and astigmatism on a mobile phone -- ie measurements for eyeglasses. Through Test2Connect, EyeNetra's cloud-based platform for eye care, and EyeNetra's suite of mobile eye diagnostics, patients can connect to care providers and vendors (eg eyeglass stores, hospitals, doctors, pharmaceuticals, and more) with actionable measurements at or close to home.
Type of partnerships sought: We are looking for venture capital and angel investment as well as partners for distribution, manufacture and clinical evaluations in the US and abroad.
(1)
(1)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼